Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

ABSTRACT: The metastatic burden is a critical factor for decision-making in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). This study aimed to develop and validate a novel risk model for survival in patients with de novo low- and high-burden metastatic HSPC. The retrospective observational study included men with de novo metastatic prostate cancer who were treated with primary androgen-deprivation therapy at 30 institutions across Japan between 2008 and 2017. We created a risk model for overall survival (OS) in the discovery cohort (n = 1449) stratified by the metastatic burden (low vs high) and validated its predictive ability in a separate cohort (n = 951). Based on multivariate analyses, lower hemoglobin levels, higher Gleason grades, and higher clinical T-stage were associ

SUBMITTER: Shiota M 

PROVIDER: S-EPMC8409413 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature